LRIG1 and experimental autoimmune encephalomyelitis: Agonistic monoclonal antibody (mAb) specific to Lrig1 or adoptive transfer of CD4+Lrig1+ T cells exhibits significant therapeutic efficacy in experimental autoimmune encephalomyelitis (EAE), IBD, and lupus animal models.